A follow-up to QROT-067, in which I included audio from a pair of doctors testifying at a state house subcommittee the problem of the "big pharma solution" is that it stimulated almost no IgA, which is vital for the solution to actually treat a respiratory illnesses.

The source, an NIH article*:

"Most [sacred-cowed big pharma solutions] are delivered intramuscularly, and mucosal immunity and IgA secretion IS THEREBY MINIMAL. Furthermore, ELICITING IgA PRODUCTION from conventional vaccines is DIFFICULT, and [sacred-cowed big pharma solutions] may LACK the immunogenicity required to elicit NECESSARY IgA PROTECTION."
 
"... respiratory viruses are ESPECIALLY DIFFICULT to protect against with [the usual solution]."

"One reason for... FAILURE against respiratory viruses is that the respiratory tract, including the lungs, is an external surface that is PROTECTED BY THE GENERATION OF IGA ANTIBODIES; yet, the antibodies measured to determine whether an experimental subject has 'responded' . . . often focus on IgG, IgM, or total immunoglobulin in the blood. "

Thanks for listening. I am not on social media much, so please "like" directly on the podcast or specific episode. Also, activate notifications so you can more consistently find out about episodes to which you may want to listen

*COVID-19 . . . Frontrunners and Their Nanotechnology Design"
Note though that I referred in the podcast to this as a study. It is a review.